U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07450378) titled 'QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)' on Feb. 27.
Brief Summary: This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 Treatment in adults with Heterozygous Familial Hypercholesterolemia on a stable lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a placebo according to the study schedule.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Heterozygous Familial Hypercholesterolemia (HeFH)
Intervention:
DRUG: QLC7401 Injection
QLC7401 is a small interfering RNA (siRNA) targeti...